Company Overview - Kenvue Inc. is a consumer health company offering well-known brands in pain management, skin and beauty, oral care, and cough, cold, and allergy care, including Tylenol, Listerine, and Neutrogena [1] Earnings Report - Kenvue is set to report its Q3 2025 earnings on November 6, with Wall Street analysts expecting an EPS of $0.27, a decrease from $0.28 in the prior-year period [2] - Quarterly revenue is anticipated to be $3.86 billion, down from $3.90 billion a year earlier [2] - The company reported Q2 2025 earnings on August 7, posting adjusted EPS of $0.29, which beat the consensus estimate of $0.28, while revenues of $3.84 billion fell short of the consensus of $3.94 billion [3] Financial Outlook - The CFO stated that the outlook for 2025 is being adjusted to reflect year-to-date results and expectations for the second half of the year, considering the dynamic external environment [4] - For the full year 2025, Kenvue expects net sales and organic sales to decline by low single digits [4] Dividend Information - Kenvue's dividend yield is currently 4.58%, with a total of $0.83 per share paid in dividends over the last 12 months [2] - To earn $100 per month from Kenvue dividends, an investment of approximately $26,201 is required, which equates to around 1,420 shares at a price of $18.45 each [5][6]
Here's How You Can Earn $100 In Passive Income By Investing In Kenvue Stock